JPRN-UMIN000003990已完成1 期
A Phase I /II Study of Bi-weekly XELIRI with Bevacizumab for patient with Metastatic Colorectal Cancer as second-line chemotherapy. - BIXER study
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Treatment with tegafur gimestat otastat potassium within 7 days (2) Need to drain malignant coelomic fluid. (3) Jaundice (4) Paralytic or mechanical bowel obstruction (5) Receiving Atazanavir Sulfate (6) Radiological evidence of CNS metastases or brain cancer (7) Multiple primary cancer within 5 years. (8) Complication of cerebrovascular disease or symptoms within 1 year. (9) Any surgical treatments including skin-open biopsy, trauma surgery and other more intensive surgery within 4 weeks or aspiration biopsy within one week. (10) Administering antithrombotic drug within 10 days. (11) Need to administrate or having anti-platelets therapy (including Methotrexate aspirin and NSAIDS) (12) Evidence of bleeding diathesis or coagulopathy. (13) Active gastrointestinal ulcer (14) Current or previous (within the last 1 year) history of GI perforation (15) Non healing fracture (16) Renal failure to be treated, 2+ or higher proteinuria within 2 weeks prior to entry (17)Uncontrolled Hypertension (18) Uncontrolled diabetes mellitus (19) Clinically significant (i.e. active) cardiovascular disease, or past or current history (within the last 1 year) of myocardial infarction (20) History of the serious hypersensitivity for Fluorouracil or bevacizumab (21) Evidence of interstinal lung disease, or pulmonary fibrosis (22) History of organ transplantation (23) Treatment history of irinotecan (24) Other conditions not suitable for this study
研究者
相似试验
已完成
1 期
A Phase I /II Study of Tri-weekly XELIRI with Bevacizumab for patient with Metastatic Colorectal Cancer as second-line chemotherapy.colorectal cancerJPRN-UMIN000003482Epidemiological and Clinical research Information Network (ECRIN)33
已完成
2 期
A Phase II Study of Tri-weekly XELIRI with Bevacizumab for patient with unresectable or recurrent Colorectal Cancer as first -line chemotherapy.Colorectal CancerJPRN-UMIN000006070Kyushu Study group of Clinical Cancer35
已完成
2 期
A Phase II Study of Bi-weekly XELIRI with Bevacizumab for patient with Metastatic Colorectal Cancer as second-line chemotherapyadvanced and/or recurrent colorectal cancerJPRN-UMIN000009280PO Japan Southwest Oncology Research Support Organization(JSWOG)51
已完成
2 期
A Phase II Study of Bi-weekly XELOX with Bevacizumab for patient with Metastatic Colorectal Cancer as first-line chemotherapyJPRN-UMIN000010259Yamaguchi University Graduate School of Medicibe, Digestive surgery and surgical oncology45
已完成
2 期
Multicenter Phase II Study of XELOX with Bevacizumab in the Late Elderly Patients with Unresectable Advanced/Recurrent Colorectal Cancercolorectal cancerJPRN-UMIN000003500Epidemiological and Clinical Research Information Network (ECRIN)35